Litcius/Paper detail

Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US Food and Drug Administration adverse events reporting system analysis and a review of the literature

Kathleen P. L. Cheok, Adrian Farrow, Deborah Springell, Maeve O’Reilly, Simon Morley, Neil Stone, Claire Roddie

2024The Lancet Infectious Diseases10 citationsDOI

Topics & Concepts

MucormycosisMedicineChimeric antigen receptorAdverse effectIntensive care medicineContext (archaeology)PharmacotherapySurgeryInternal medicineImmunotherapyCancerBiologyPaleontologyAntifungal resistance and susceptibilityCAR-T cell therapy researchFungal Infections and Studies
Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US Food and Drug Administration adverse events reporting system analysis and a review of the literature | Litcius